Medifast, Inc. Announces First Quarter 2019 Financial Results
Company Added
Company Removed
Apply to Request List

Medifast, Inc. Announces First Quarter 2019 Financial Results

  • First Quarter Revenue Increased 68% to $165.9 Million
  • Net Income Increased 70% for the First Quarter
  • Company Raises Full Year 2019 Outlook

BALTIMORE, May 1, 2019 // PRNewswire // - Medifast, Inc. (NYSE: MED), a leading manufacturer and distributor of healthy living products and programs, today reported financial results for the first quarter ended March 31, 2019.

First Quarter 2019 Highlights:

  • Revenue of $165.9 million, an increase of 68.2% year-over-year
  • Active earning OPTAVIA Coaches of 27,200, an increase of 62.9% year-over-year
  • Net income of $20.8 million, an increase of 69.8% year-over-year
  • Earnings per diluted share ("EPS") of $1.70, an increase of 68.3% year-over-year
  • Cash, cash equivalents, and investment securities of $120.4 million and debt-free
  • Quarterly cash dividend of $9.1 million, or $0.75 per share, declared March 13, 2019 and payable in the second quarter of 2019

"Our strong start to the year was fueled by a record number of active earning OPTAVIA Coaches and increased coach productivity," commented Dan Chard, Medifast's Chief Executive Officer. "These achievements helped generate first quarter revenue and earnings above our expectations and gives us confidence to raise our outlook for the full year 2019. Going forward, we believe Medifast remains well positioned to deliver long-term sustainable growth and value for our stockholders as well as meaningful improvements to the lives of OPTAVIA clients through our growing community of OPTAVIA Coaches who join us in helping clients achieve optimal health and wellbeing."

First Quarter 2019 Results

For the first quarter of 2019, revenue increased 68.2% to $165.9 million from revenue of $98.6 million for the first quarter of 2018. OPTAVIA-branded products represented 73% of consumable units sold for the first quarter of 2019 compared to 58% for the first quarter of last year. The total number of active earning OPTAVIA Coaches for the first quarter of 2019 increased to 27,200, compared to 16,700 for the first quarter of 2018. The average revenue per active earning OPTAVIA Coach for the first quarter of 2019 increased 10.2% to $5,817 compared to $5,278 for the first quarter last year.

Gross profit for the first quarter of 2019 increased to $125.1 million from $74.8 million for the first quarter of 2018. The Company's gross profit as a percentage of revenue decreased 50 basis points to 75.4% from 75.9% for the first quarter last year. The decrease in gross margin percentage was a result of higher obsolescence and shipping costs.

Selling, general and administrative expenses ("SG&A") for the first quarter of 2019 increased $40.3 million to $100.4 million compared to $60.1 million for the first quarter of 2018, primarily as a result of higher OPTAVIA commissions expense, increased salaries and benefits, increased consulting costs related to information technology projects, and increased credit card fees resulting from higher sales. SG&A as a percentage of sales decreased 50 basis points to 60.5% of revenue compared to 61.0% in the first quarter of 2018.

Operating income increased $10.0 million to $24.7 million from $14.7 million for the first quarter of 2018 primarily as a result of increased gross profit, partially offset by increased SG&A expenses. Operating income as a percentage of revenue was 14.9% for the first quarter of 2019 and 2018, respectively.

The first quarter 2019 effective tax rate was 17.1%, compared to 18.1% for the first quarter of 2018. This decrease was primarily a result of a 2.4% decrease relating to the discrete accounting for taxes associated with share-based compensation offset by a 3.5% benefit from the net operating loss due to state apportionment.

Net income for the first quarter of 2019 was $20.8 million, or $1.70 per diluted share, based on approximately 12.2 million shares outstanding. First quarter 2018 net income was $12.2 million, or $1.01 per diluted share based on approximately 12.1 million shares outstanding.

Balance Sheet

The Company's balance sheet remains strong with stockholders' equity of $122.1 million and working capital of $92.4 million as of March 31, 2019. Cash, cash equivalents, and investment securities increased $19.4 million to $120.4 million as of March 31, 2019 compared to $101.0 million at December 31, 2018. The Company remains free of interest bearing debt. Inventory increased $4.4 million to $43.3 million at March 31, 2019 compared to $38.9 million at December 31, 2018 as the Company increased inventory levels to meet current and anticipated customer demand. The Company declared a quarterly cash dividend of $9.1 million, or $0.75 per share, during the first quarter of 2019.

Outlook

The Company expects second quarter revenue to be in the range of $180 million to $185 million and EPS to be in the range of $1.67 to $1.72. For the full year 2019, the Company now expects revenue of $720 million to $740 million and EPS of $6.70 to $6.90, compared to the Company's previous guidance for revenue of $700 million to $720 million and EPS of $6.45 to $6.65. The full year 2019 earnings guidance assumes a 21.5% to 22.5% effective tax rate. The Company expects the 2019 cadence of spending to be similar to 2018 with its annual convention spend occurring in the third quarter of the year and the cost of a 2020 Leadership Advancement event to be incurred in the third and fourth quarters of the year.

Conference Call Information

The conference call is scheduled for today, Wednesday, May 1, 2019 at 4:30 p.m. ET. The call will be broadcast live over the Internet hosted at the Investor Relations section of Medifast's website at www.MedifastInc.com, and will be archived online through May 15, 2019. In addition, listeners may dial (855) 560-2579.

A telephonic playback will be available from 6:30 p.m. ET, May 1, 2019, through May 8, 2019. Participants can dial (877) 344-7529 to hear the playback and enter passcode 10130924.

About Medifast®

Medifast (NYSE: MED) is a leading manufacturer and distributor of clinically proven, healthy living products and programs. The brand has been recommended by more than 20,000 doctors since its founding. Its integrated coach model leverages nearly 40 years of experience from medical, franchise, e-commerce, and direct selling channels. Medifast and its community of independent OPTAVIA Coaches embrace the future of wellness with a shared vision to offer the world lifelong transformation, one healthy habit at a time™. OPTAVIA® is represented by a community of OPTAVIA Coaches who teach Clients healthy habits, while offering support and guidance on their transformation journey. In 2018, Medifast announced it will expand into the Asia-Pacific markets of Hong Kong and Singapore in 2019 with its integrated coach model. Medifast is traded on the New York Stock Exchange and was named to Forbes' 100 Most Trustworthy Companies in America List in 2016 and 2017. For more information, visit www.MedifastInc.com or www.OPTAVIA.com.

MED-F

Forward Looking Statements

Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend," "anticipate," "expects" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Medifast believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Medifast's inability to attract and retain independent OPTAVIA Coaches and clients, increases in competition, litigation, regulatory changes, and its planned growth into new domestic and international markets and new channels of distribution. Although Medifast believes that the expectations, statements, and assumptions reflected in these forward- looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

(in thousands, except per share amounts & dividend data)

 
   

Three months ended March 31,

   

2019

 

2018

             

Revenue

 

$

165,876

 

$

98,596

Cost of sales

   

40,729

   

23,788

Gross profit

   

125,147

   

74,808

             

Selling, general, and administrative

   

100,432

   

60,125

             

Income from operations

   

24,715

   

14,683

             

Other income (expense)

           

Interest income, net

   

312

   

249

Other income (expense)

   

(6)

   

(1)

     

306

   

248

             

Income from operations before income taxes

   

25,021

   

14,931

             

Provision for income taxes

   

4,271

   

2,709

             

Net income

 

$

20,750

 

$

12,222

             

Earnings per share - basic

 

$

1.75

 

$

1.02

             

Earnings per share - diluted

 

$

1.70

 

$

1.01

             

Weighted average shares outstanding -

           

Basic

   

11,880

   

12,030

Diluted

   

12,240

   

12,139

             

Cash dividends declared per share

 

$

0.75

 

$

0.48

             

 

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(in thousands, except par value)

               
       

March 31,

   

December 31,

       

2019

   

2018

               

ASSETS

Current Assets

             

Cash and cash equivalents

   

$

101,842

 

$

81,364

Accounts receivable-net of doubtful accounts of $270 and $394 at

         

March 31, 2019 and December 31, 2018, respectively

     

631

   

1,011

Inventory

     

43,257

   

38,888

Investment securities

     

18,585

   

19,670

Prepaid expenses and other current assets

     

4,995

   

4,586

Total current assets

     

169,310

   

145,519

               

Property, plant and equipment - net

     

23,343

   

19,747

Right-of-use asset

     

12,864

   

-

Other assets

     

941

   

1,183

Deferred tax assets

     

3,612

   

2,980

               
               

TOTAL ASSETS

   

$

210,070

 

$

169,429

               

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities

             

Accounts payable and accrued expenses

   

$

74,452

 

$

60,323

Current lease obligation

     

2,443

   

-

Total current liabilities

     

76,895

   

60,323

               

Lease obligation, less current lease obligation

     

11,107

   

-

Total liabilities

     

88,002

   

60,323

               

Stockholders' Equity

             

Common stock, par value $.001 per share: 20,000 shares authorized;

         

12,126 and 12,117 issued and 11,898 and 11,868 outstanding

         

at March 31, 2019 and December 31, 2018, respectively

 

12

   

12

Additional paid-in capital

     

9,805

   

8,802

Accumulated other comprehensive loss

     

(46)

   

(173)

Retained earnings

     

143,176

   

131,344

Less: Treasury stock at cost, 193 shares at March 31, 2019 and
December 31, 2018, respectively

 

(30,879)

   

(30,879)

Total stockholders' equity

     

122,068

   

109,106

               

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

   

$

210,070

 

$

169,429

               

SOURCE Medifast, Inc.

###

Comments:

comments powered by Disqus
Share This Page

Subscribe to Our Newsletters